An update in the use of antibodies to treat glioblastoma multiforme

Autoimmune Diseases

Volumn 2013, Issue , 2013, Pages

  Hernández Pedro, Norma Y ^a   Rangel López, Edgar ^a   Vargas Félix, Gustavo ^a   Pineda, Benjamín ^a   Sotelo, Julio ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; ANTIBODY; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CABOZANTINIB; CEDIRANIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN G1 ANTIBODY; IRINOTECAN; LENVATINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; NIMOTUZUMAB; OLARATUMAB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; RINDOPEPIMUT; SEMAXANIB; SUNITINIB; TEMOZOLOMIDE; TREBANANIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BLEEDING; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FATIGUE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; KIDNEY CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; METASTASIS; METHYLATION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMATITIS; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR INVASION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VASCULARIZATION; WOUND;

EID: 84888863667     PISSN: None     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2013/716813     Document Type: Review

References (123)

1. Weiner L. M., Surana R., Wang S., Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology 2010 10 5 317 327 2-s2.0-77951614830 10.1038/nri2744
2. Ohgaki H., Kleihues P., Genetic pathways to primary and secondary glioblastoma. The American Journal of Pathology 2007 170 5 1445 1453 2-s2.0-34250877865 10.2353/ajpath.2007.070011 (Pubitemid 47339290)
3. Reardon D. A., Egorin M. J., Desjardins A., Vredenburgh J. J., Beumer J. H., Lagattuta T. F., Gururangan S., Herndon J. E. II, Salvado A. J., Friedman H. S., Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 2009 115 10 2188 2198 2-s2.0-65649146868 10.1002/cncr.24213
4. Gerstner E. R., Eichler A. F., Plotkin S. R., Drappatz J., Doyle C. L., Xu L., Duda D. G., Wen P. Y., Jain R. K., Batchelor T. T., Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. Journal of Neuro-Oncology 2011 103 2 325 332 2-s2.0-79959841782 10.1007/s11060-010-0390-7
5. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z., Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal 1999 13 1 9 22 2-s2.0-0032907687 (Pubitemid 29038270)
6. Jain R. K., Duda D. G., Clark J. W., Loeffler J. S., Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology 2006 3 1 24 40 2-s2.0-30944446883 10.1038/ncponc0403 (Pubitemid 43108832)
7. Verheul H. M., Pinedo H. M., The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clinical Breast Cancer 2000 1 supplement 1 S80 84 2-s2.0-0002957530
8. Traxler P., Allegrini P. R., Brandt R., Brueggen J., Cozens R., Fabbro D., Grosios K., Lane H. A., McSheehy P., Mestan J., Meyer T., Tang C., Wartmann M., Wood J., Caravatti G., AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Research 2004 64 14 4931 4941 2-s2.0-3142774878 10.1158/0008-5472.CAN-03-3681 (Pubitemid 38924540)
9. Díaz-Rubio E., Vascular endothelial growth factor inhibitors in colon cancer. Advances in Experimental Medicine and Biology 2006 587 251 275 2-s2.0-34247602358
10. Kreitman R. J., Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009 23 1 1 13 2-s2.0-64349108724 10.2165/00063030-200923010-00001
11. Greenfield L., Johnson V. G., Youle R. J., Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987 238 4826 536 539 2-s2.0-0023205060 (Pubitemid 17147040)
12. Williams D. P., Parker K., Bacha P., Bishai W., Borowski M., Genbauffe F., Strom T. B., Murphy J. R., Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Engineering 1987 1 6 493 498 2-s2.0-0023529699
13. Shapira A., Benhar I., Toxin-based therapeutic approaches. Toxins 2010 2 11 2519 2583 2-s2.0-79952265972 10.3390/toxins2112519
14. Siegall C. B., Chaudhary V. K., FitzGerald D. J., Pastan I., Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. Journal of Biological Chemistry 1989 264 24 14256 14261 2-s2.0-0024384846 (Pubitemid 19214253)
15. Pastan I., Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunology, Immunotherapy 2003 52 5 338 341 2-s2.0-0038290547 (Pubitemid 36578027)
16. Jørgensen R., Purdy A. E., Fieldhouse R. J., Kimber M. S., Bartlett D. H., Merrill A. R., Cholix toxin, a novel ADP-ribosylating factor from Vibrio cholerae. Journal of Biological Chemistry 2008 283 16 10671 10678 2-s2.0-44849084557 10.1074/jbc.M710008200
17. Sarnovsky R., Tendler T., Makowski M., Kiley M., Antignani A., Traini R., Zhang J., Hassan R., FitzGerald D. J., Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin. Cancer Immunology, Immunotherapy 2010 59 5 737 746 2-s2.0-77950473461 10.1007/s00262-009-0794-4
18. Vitetta E. S., Thorpe P. E., Uhr J. W., Immunotoxins: magic bullets or misguided missiles? Immunology Today 1993 14 6 252 259 2-s2.0-0027156735 (Pubitemid 23186986)
19. Pastan I., Hassan R., FitzGerald D. J., Kreitman R. J., Immunotoxin treatment of cancer. Annual Review of Medicine 2007 58 221 237 (Pubitemid 46706511)
20. Mathew M., Verma R. S., Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Science 2009 100 8 1359 1365 2-s2.0-67650678448 10.1111/j.1349-7006.2009.01192.x
21. Budel L. M., Touw I. P., Delwel R., Clark S. C., Lowenberg R., Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. Blood 1989 74 2 565 571 2-s2.0-0024360582 (Pubitemid 19208794)
22. Messmann R. A., Vitetta E. S., Headlee D., Senderowicz A. M., Figg W. D., Schindler J., Michiel D. F., Creekmore S., Steinberg S. M., Kohler D., Jaffe E. S., Stetler-Stevenson M., Chen H., Ghetie V., Sausville E. A., A phase I study of combination therapy with immunotoxins IgG-HD37- deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clinical Cancer Research 2000 6 4 1302 1313 2-s2.0-0034092593 (Pubitemid 30226212)
23. Herrera L., Bostrom B., Gore L., Sandler E., Lew G., Schlegel P. G., Aquino V., Ghetie V., Vitetta E. S., Schindler J., A phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 2009 31 12 936 941 2-s2.0-73949122603 10.1097/MPH.0b013e3181bdf211
24. Schnell R., Vitetta E., Schindler J., Barth S., Winkler U., Borchmann P., Hansmann M. L., Diehl V., Ghetie V., Engert A., Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leukemia and Lymphoma 1998 30 5-6 525 537 2-s2.0-7344268577 (Pubitemid 28393687)
25. Schnell R., Staak O., Borchmann P., Schwartz C., Matthey B., Hansen H., Schindler J., Ghetie V., Vitetta E. S., Diehl V., Engert A., A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clinical Cancer Research 2002 8 6 1779 1786 2-s2.0-0036285666 (Pubitemid 34633735)
26. Xu Y., Xu Q., Rosenblum M. G., Scheinberg D. A., Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice. Leukemia 1996 10 2 321 326 2-s2.0-0029878810 (Pubitemid 26102891)
27. Dean A., Talpaz M., Kantarjian H., Faderl S., Jabbour E., Ravandi Kashani F., 'Brien S. M. O., Rosenblum M., Cortes J. E., Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies. Journal of Clinical Oncology 2010 28 15 supplment
28. Olsen E., Duvic M., Frankel A., Kim Y., Martin A., Vonderheid E., Jegasothy B., Wood G., Gordon M., Heald P., Oseroff A., Pinter-Brown L., Bowen G., Kuzel T., Fivenson D., Foss F., Glode M., Molina A., Knobler E., Stewart S., Cooper K., Stevens S., Craig F., Reuben J., Bacha P., Nichols J., Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology 2001 19 2 376 388 2-s2.0-0035863468 (Pubitemid 32112849)
29. Chang K., Pastan I., Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proceedings of the National Academy of Sciences of the United States of America 1996 93 1 136 140 2-s2.0-0030069718 10.1073/pnas.93.1.136 (Pubitemid 26041483)
30. Giamas G., Man Y. L., Hirner H., Bischof J., Kramer K., Khan K., Lavina Ahmed S. S., Stebbing J., Knippschild U., Kinases as targets in the treatment of solid tumors. Cellular Signalling 2010 22 7 984 1002 2-s2.0-77952291403 10.1016/j.cellsig.2010.01.011
31. Carpenter G., Cohen S., Epidermal growth factor. Journal of Biological Chemistry 1990 265 14 7709 7712 2-s2.0-0025321157 (Pubitemid 20158927)
32. Wikstrand G. J., Reist C. J., Archer G. E., Zalutsky M. R., Bigner D. D., The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. Journal of NeuroVirology 1998 4 2 148 158 2-s2.0-7144261725 (Pubitemid 28167490)
33. Nishikawa R., Ji X.-D., Harmon R. C., Lazar C. S., Gill G. N., Cavenee W. K., Huang H.-J. S., A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proceedings of the National Academy of Sciences of the United States of America 1994 91 16 7727 7731 2-s2.0-0028146767 10.1073/pnas.91.16.7727 (Pubitemid 24238258)
34. Su Huang H.-J., Nagane M., Klingbeil C. K., Lin H., Nishikawa R., Ji X.-D., Huang C.-M., Gill G. N., Wiley H. S., Cavenee W. K., The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. Journal of Biological Chemistry 1997 272 5 2927 2935 2-s2.0-14444288522 10.1074/jbc.272.5.2927 (Pubitemid 27053343)
35. Zhang Y., Guessous F., Kofman A., Schiff D., Abounader R., XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010 13 2 112 121 2-s2.0-77749240452
36. Frederick L., Wang X.-Y., Eley G., James C. D., Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Research 2000 60 5 1383 1387 2-s2.0-0034163550 (Pubitemid 30152011)
37. Feldkamp M. M., Lala P., Lau N., Roncari L., Guha A., Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999 45 6 1442 1453 2-s2.0-0032763824
38. Negri D. R. M., Tosi E., Valota O., Ferrini S., Cambiaggi A., Sforzini S., Silvani A., Ruffini P. A., Colnaghi M. I., Canevari S., In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. British Journal of Cancer 1995 72 4 928 933 2-s2.0-0028826233
39. Mishima K., Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Research 2001 61 14 5349 5354 2-s2.0-0035887147 (Pubitemid 32694908)
40. Patel D., Lahiji A., Patel S., Franklin M., Jimenez X., Hicklin D. J., Kang X., Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Research 2007 27 5 3355 3366 2-s2.0-35349025929 (Pubitemid 47607562)
41. Sampson J. H., Crotty L. E., Lee S., Archer G. E., Ashley D. M., Wikstrand C. J., Hale L. P., Small C., Dranoff G., Friedman A. H., Friedman H. S., Bigner D. D., Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proceedings of the National Academy of Sciences of the United States of America 2000 97 13 7503 7508 2-s2.0-12944309909 10.1073/pnas.130166597 (Pubitemid 30431493)
42. Neyns B., Sadones J., Joosens E., Bouttens F., Verbeke L., Baurain J.-F., D'Hondt L., Strauven T., Chaskis C., In't Veld P., Michotte A., De Greve J., Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Annals of Oncology 2009 20 9 1596 1603 2-s2.0-69849112085 10.1093/annonc/mdp032
43. Moserle L., Amadori A., Indraccolo S., The angiogenic switch: implications in the regulation of tumor dormancy. Current Molecular Medicine 2009 9 8 935 941 2-s2.0-70350736093 10.2174/156652409789712800
44. Wedge S. R., Kendrew J., Hennequin L. F., Valentine P. J., Barry S. T., Brave S. R., Smith N. R., James N. H., Dukes M., Curwen J. O., Chester R., Jackson J. A., Boffey S. J., Kilburn L. L., Barnett S., Richmond G. H. P., Wadsworth P. F., Walker M., Bigley A. L., Taylor S. T., Cooper L., Beck S., Jürgensmeier J. M., Ogilvie D. J., AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Research 2005 65 10 4389 4400 2-s2.0-20144370978 10.1158/0008-5472.CAN-04-4409 (Pubitemid 40775678)
45. Alitalo K., Carmeliet P., Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002 1 3 219 227 2-s2.0-0036527585 10.1016/S1535-6108(02)00051-X (Pubitemid 41039145)
46. Okamoto K., Neureiter D., Alinger B., Meissnitzer M., Sass G., Schmitz V., Di Fazio P., Wissniowski T., Gahr S., Hohenstein B., Kaufmann B., Schlösser A., Haus U., Hahn E. G., Herold C., Ocker M., The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. International Journal of Oncology 2008 33 4 733 742 2-s2.0-54049147744 10.3892/ijo-00000059
47. Reardon D. A., Conrad C. A., Cloughesy T., Prados M. D., Friedman H. S., Aldape K. D., Mischel P., Xia J., DiLea C., Huang J., Mietlowski W., Dugan M., Chen W., Yung W. K. A., Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology 2012 69 6 1507 1518 2-s2.0-84857665711 10.1007/s00280-012-1854-6
48. Batchelor T. T., Mulholland P., Neyns B., Nabors L. B., Campone M., Wick A., Mason W., Mikkelsen T., Phuphanich S., Ashby L. S., Degroot J., Gattamaneni R., Cher L., Rosenthal M., Payer F., Jürgensmeier J. M., Jain R. K., Sorensen A. G., Xu J., Liu Q., van den Bent M., Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of Clinical Oncology 2013 31 26 3212 3218
49. Iwamoto F. M., Lamborn K. R., Robins H. I., Mehta M. P., Chang S. M., Butowski N. A., DeAngelis L. M., Abrey L. E., Zhang W.-T., Prados M. D., Fine H. A., Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology 2010 12 8 855 861 2-s2.0-78149492402 10.1093/neuonc/noq025
50. Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 86 3 353 364 2-s2.0-0030576517 10.1016/S0092-8674(00)80108-7 (Pubitemid 26272076)
51. Imai K., Takaoka A., Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer 2006 6 9 714 727 2-s2.0-33747855481 10.1038/nrc1913 (Pubitemid 44286003)
52. Glen H., Mason S., Patel H., Macleod K., Brunton V. G., E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 2011 11, article 309 2-s2.0-79960554999 10.1186/1471-2407-11-309
53. Bergsland E., Hurwitx H., Fehrenbacher L., A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology 2000 19 abstract 939
54. Gordon M. S., Margolin K., Talpaz M., Sledge G.W. J., Holmgren E., Benjamin R., Stalter S., Shak S., Adelman D. C., Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Journal of Clinical Oncology 2001 19 3 843 850 2-s2.0-0035253739 (Pubitemid 32119100)
55. Sledge G., Miller K., Novotny W., A phase II trial of single agent Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proceedings of the American Society of Clinical Oncology 2000 19 abstract 5C
56. DeVore R. F., Fehrenbacher L., Herbst R. S., A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proceedings of the American Society of Clinical Oncology 2000 19 abstract 1896
57. Siegelin M. D., Raskett C. M., Gilbert C. A., Ross A. H., Altieri D. C., Sorafenib exerts anti-glioma activity in vitro and in vivo. Neuroscience Letters 2010 478 3 165 170 2-s2.0-77953611845 10.1016/j.neulet.2010.05.009
58. Gilbert M. R., First-line bevacizumab in combination with standard of care not recommended for newly diagnosed glioblastoma. Proceedings of the ASCO Annual Meeting 2013
59. Gerber H.-P., McMurtrey A., Kowalski J., Yan M., Keyt B. A., Dixit V., Ferrara N., Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. Journal of Biological Chemistry 1998 273 46 30336 30343 2-s2.0-0032515047 10.1074/jbc.273.46.30336 (Pubitemid 28545503)
60. Traxler P., Bold G., Buchdunger E., Caravatti G., Furet P., Manley P., O'Reilly T., Wood J., Zimmermann J., Tyrosine kinase inhibitors: from rational design to clinical trials. Medicinal Research Reviews 2001 21 6 499 512 2-s2.0-0034788453 10.1002/med.1022 (Pubitemid 32959239)
61. Shah G. D., Loizos N., Youssoufian H., Schwartz J. D., Rowinsky E. K., Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α Cancer 2010 116 4 supplement 1018 1026 2-s2.0-76249126427 10.1002/cncr.24788
62. Yung W. K., Friedman H., Jackson E., Provenzale J., Leeds N., Conrad C., Walker A., Henry A., Huang J., Lauren D., Dugan M., A phase I trial of PTK787/ZK22584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proceedings of the American Society of Clinical Oncology 2002 21, article 79a
63. Fong T. A. T., Shawver L. K., Sun L., Tang C., App H., Powell T. J., Kim Y. H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K. P., McMahon G., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Research 1999 59 1 99 106 2-s2.0-0032893263 (Pubitemid 29062964)
64. Geng L., Donnelly E., McMahon G., Lin P. C., Sierra-Rivera E., Oshinka H., Hallahan D. E., Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Research 2001 61 6 2413 2419 2-s2.0-0035866771 (Pubitemid 32685816)
65. Vajkoczy P., Menger M. D., Vollmar B., Schilling L., Schmiedek P., Hirth K. P., Ullrich A., Fong T. A., Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1999 1 1 31 41 2-s2.0-0033107767
66. Pietras K., Sjöblom T., Rubin K., Heldin C.-H., Östman A., PDGF receptors as cancer drug targets. Cancer Cell 2003 3 5 439 443 2-s2.0-0141486251 10.1016/S1535-6108(03)00089-8 (Pubitemid 38340290)
67. Matei D., Kelich S., Cao L., Menning N., Emerson R. E., Rao J., Meei H. J., Sledge G. W., PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biology and Therapy 2007 6 12 1951 1959 2-s2.0-42549156263 (Pubitemid 351590409)
68. Paz K., Zhu Z., Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Frontiers in Bioscience 2005 10 1415 1439 2-s2.0-31744449858
69. Spratlin J. L., Cohen R. B., Eadens M., Gore L., Camidge D. R., Diab S., Leong S., O'Bryant C., Chow L. Q. M., Serkova N. J., Meropol N. J., Lewis N. L., Chiorean E. G., Fox F., Youssoufian H., Rowinsky E. K., Eckhardt S. G., Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. Journal of Clinical Oncology 2010 28 5 780 787 2-s2.0-77649213706 10.1200/JCO.2009.23.7537
70. Reardon D. A., Groves M. D., Wen P. Y., Nabors L., Mikkelsen T., Rosenfeld S., Raizer J., Barriuso J., McLendon R. E., Suttle A. B., Ma B., Curtis C. M., Dar M. M., de Bono J., A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clinical Cancer Research 2013 19 4 900 908
71. Drappatz J., Norden A. D., Wong E. T., Doherty L. M., Lafrankie D. C., Ciampa A., Kesari S., Sceppa C., Gerard M., Phan P., Schiff D., Batchelor T. T., Ligon K. L., Young G., Muzikansky A., Weiss S. E., Wen P. Y., Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. International Journal of Radiation Oncology Biology Physics 2010 78 1 85 90 2-s2.0-77955922743 10.1016/j.ijrobp.2009.07.1741
72. Wibom C., Sandström M., Henriksson R., Antti H., Johansson M., Bergenheim A. T., Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model. International Journal of Oncology 2010 37 4 879 890 2-s2.0-77956502140 10.3892/ijo-00000739
73. Brandes A. A., Stupp R., Hau P., Lacombe D., Gorlia T., Tosoni A., Mirimanoff R. O., Kros J. M., van den Bent M. J., EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. European Journal of Cancer 2010 46 2 348 354 2-s2.0-72449155176 10.1016/j.ejca.2009.10.029
74. Batchelor T. T., Sorensen A. G., di Tomaso E., Zhang W.-T., Duda D., Cohen K. S., Kozak K. R., Cahill D. P., Chen P.-J., Zhu M., Ancukiewicz M., Mrugala M. M., Plotkin S., Drappatz J., Louis D. N., Ivy P., Scadden D., Benner T., Loeffler J. S., Wen P. Y., Jain R. K., AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007 11 1 83 95 2-s2.0-33846149645 10.1016/j.ccr.2006.11.021 (Pubitemid 46075199)
75. Batchelor T. T., Duda D. G., Di Tomaso E., Ancukiewicz M., Plotkin S. R., Gerstner E., Eichler A. F., Drappatz J., Hochberg F. H., Benner T., Louis D. N., Cohen K. S., Chea H., Exarhopoulos A., Loeffler J. S., Moses M. A., Ivy P., Sorensen A. G., Wen P. Y., Jain R. K., Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Journal of Clinical Oncology 2010 28 17 2817 2823 2-s2.0-77954720781 10.1200/JCO.2009.26.3988
76. Reardon D. A., Vredenburgh J. J., Desjardins A., Peters K. B., Sathornsumetee S., Threatt S., Sampson J. H., Herndon J. E. II, Coan A., McSherry F., Rich J. N., McLendon R. E., Zhang S., Friedman H. S., Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology 2012 108 3 499 506
77. McNamara M. G., Mason W. P., Antiangiogenic therapies in glioblastoma multiforme. Expert Review of Anticancer Therapy 2012 12 5 643 654
78. Bruheim S., Kristian A., Uenaka T., Suo Z., Tsuruoka A., Nesland J. M., Fodstad Ø., Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. International Journal of Cancer 2011 129 3 742 750 2-s2.0-79958037590 10.1002/ijc.25922
79. Alvarez R. H., Kantarjian H. M., Cortes J. E., Biology of platelet-derived growth factor and its involvement in disease. Mayo Clinic Proceedings 2006 81 9 1241 1257 2-s2.0-33748175142 10.4065/81.9.1241 (Pubitemid 44316290)
80. Yang F., Brown C., Buettner R., Hedvat M., Starr R., Scuto A., Schroeder A., Jensen M., Jove R., Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Molecular Cancer Therapeutics 2010 9 4 953 962 2-s2.0-77950833182 10.1158/1535-7163.MCT-09-0947
81. Hainsworth J. D., Ervin T., Friedman E., Priego V., Murphy P. B., Clark B. L., Lamar R. E., Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2010 116 15 3663 3669 2-s2.0-77955363593 10.1002/cncr.25275
82. Abounader R., Laterra J., Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-Oncology 2005 7 4 436 451 2-s2.0-27644543354 10.1215/S1152851705000050 (Pubitemid 41555616)
83. Arrieta O., Garcia E., Guevara P., Garcia-Navarrete R., Ondarza R., Rembao D., Sotelo J., Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 2002 94 12 3210 3218 2-s2.0-0037096867 10.1002/cncr.10594 (Pubitemid 34670504)
84. Lamszus K., Laterra J., Westphal M., Rosen E. M., Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. International Journal of Developmental Neuroscience 1999 17 5-6 517 530 2-s2.0-0032844762 10.1016/S0736-5748(99)00008-8 (Pubitemid 29421838)
85. Eder J. P., Vande Woude G. F., Boerner S. A., Lorusso P. M., Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clinical Cancer Research 2009 15 7 2207 2214 2-s2.0-65249122512 10.1158/1078-0432.CCR-08-1306
86. Gao C. F., Vande Woude G. F., HGF/SF-Met signaling in tumor progression. Cell Research 2005 15 1 49 51 2-s2.0-19644395911 10.1038/sj.cr.7290264 (Pubitemid 41653965)
87. Rosen E. M., Laterra J., Joseph A., Jin L., Fuchs A., Way D., Witte M., Weinand M., Goldberg I. D., Scatter factor expression and regulation in human glial tumors. International Journal of Cancer 1996 67 2 248 255 (Pubitemid 26274157)
88. Koochekpour S., Jeffers M., Rulong S., Taylor G., Klineberg E., Hudson E. A., Resau J. H., Vande Woude G. F., Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Research 1997 57 23 5391 5398 2-s2.0-0030690583 (Pubitemid 27516379)
89. Moriyama T., Kataoka H., Kawano H., Yokogami K., Nakano S., Goya T., Uchino H., Koono M., Wakisaka S., Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Letters 1998 124 2 149 155 2-s2.0-0032570637 10.1016/S0304-3835(97)00469-2 (Pubitemid 28073681)
90. Schmidt N. O., Westphal M., Hagel C., Ergün S., Stavrou D., Rosen E. M., Lamszus K., Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. International Journal of Cancer 1999 84 1 10 18 (Pubitemid 29059101)
91. Laterra J., Nam M., Rosen E., Rao J. S., Lamszus K., Goldberg I. D., Johnston P., Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Laboratory Investigation 1997 76 4 565 577 2-s2.0-0030975492 (Pubitemid 27176109)
92. Cao B., Su Y., Oskarsson M., Zhao P., Kort E. J., Fisher R. J., Wang L.-M., Vande Woude G. F., Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proceedings of the National Academy of Sciences of the United States of America 2001 98 13 7443 7448 2-s2.0-0035912757 10.1073/pnas.131200498 (Pubitemid 32567968)
93. Nguyen T. H., Loux N., Dagher I., Vons C., Carey K., Briand P., Hadchouel M., Franco D., Jouanneau J., Schwall R., Weber A., Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Therapy 2003 10 11 840 849 2-s2.0-0242523141 10.1038/sj.cgt.7700640 (Pubitemid 37414114)
94. Martens T., Schmidt N.-O., Eckerich C., Filibrandt R., Merchant M., Schwall R., Westphal M., Lamszus K., A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clinical Cancer Research 2006 12 20 6144 6152 2-s2.0-33750683969 10.1158/1078-0432.CCR-05-1418 (Pubitemid 44703780)
95. Bosch F., Rosich L., The contributions of paul ehrlich to pharmacology: a tribute on the occasion of the centenary of his nobel prize. Pharmacology 2008 82 3 171 179 2-s2.0-48449087282 10.1159/000149583
96. Kreitman R. J., Immunotoxins for targeted cancer therapy. AAPS Journal 2006 8 3, article 63 E532 E551 2-s2.0-33748309412 10.1208/aapsj080363 (Pubitemid 44321317)
97. Choudhary S., Mathew M., Verma R. S., Therapeutic potential of anticancer immunotoxins. Drug Discovery Today 2011 16 11-12 495 503 2-s2.0-79958187876 10.1016/j.drudis.2011.04.003
98. Janthur W. D., Cantoni N., Mamot C., Drug conjugates such as antibody drug conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. International Journal of Molecular Sciences 2012 13 12 16020 16045
99. Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S.-M., Lee T., Pope S. H., Riordan G. S., Whitlow M., Single-chain antigen-binding proteins. Science 1988 241 4877 423 426 2-s2.0-0024293979
100. Huston J. S., Levinson D., Mudgett-Hunter M., Tai M.-S., Novotny J., Margolies M. N., Ridge R. J., Bruccoleri R. E., Haber E., Crea R., Oppermann H., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America 1988 85 16 5879 5883 2-s2.0-0004198722
101. Reiter Y., Pai L. H., Brinkmann U., Wang Q.-C., Pastan I., Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Research 1994 54 10 2714 2718 2-s2.0-0028275863 (Pubitemid 24173763)
102. Pappenheimer A. M. Jr., Diphtheria toxin. Annual Review of Biochemistry 1977 46 69 94 2-s2.0-0017620769 (Pubitemid 8252139)
103. Yamaizumi M., Mekada E., Uchida T., Okada Y., One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978 15 1 245 250 2-s2.0-0018167496 (Pubitemid 9027527)
104. Boquet P., Silverman M. S., Pappenheimer A. M. Jr., Interaction of diphtheria toxin with mammalian cell membranes. Progress in Clinical and Biological Research 1977 17 501 509 2-s2.0-0017641035
105. Varol B., Bektaş M., Nurten R., Bermek E., The cytotoxic effect of diphtheria toxin on the actin cytoskeleton. Cellular & Molecular Biology Letters 2012 17 1 49 61 2-s2.0-84859920446
106. Liu T. F., Hall P. D., Cohen K. A., Willingham M. C., Cai J., Thorburn A., Frankel A. E., Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clinical Cancer Research 2005 11 1 329 334 2-s2.0-11344291098 (Pubitemid 40075812)
107. Johnson V. G., Wilson D., Greenfield L., Youle R. J., The role of the diphtheria toxin receptor in cytosol translocation. Journal of Biological Chemistry 1988 263 3 1295 1300 2-s2.0-0023838032 (Pubitemid 18043824)
108. Weaver M., Laske D. W., Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) therapy of malignant gliomas. Journal of Neuro-Oncology 2003 65 1 3 13 2-s2.0-0344876636 10.1023/A:1026246500788 (Pubitemid 37441310)
109. Nicholls P. J., Youle R. J., The structure of Pseudomonas exotoxin A as a guide to rational design. Targeted Diagnosis and Therapy 1992 7 439 446 2-s2.0-0026456337
110. Kondo T., FitzGerald D., Chaudhary V. K., Adhya S., Pastan I., Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. Journal of Biological Chemistry 1988 263 19 9470 9475 2-s2.0-0023888286
111. Batra J. K., Kasprzyk P. G., Bird R. E., Pastan I., King C. R., Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proceedings of the National Academy of Sciences of the United States of America 1992 89 13 5867 5871 2-s2.0-0026755810 10.1073/pnas.89.13.5867
112. Brinkmann U., Pai L. H., FitzGerald D. J., Willingham M., Pastan I., B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proceedings of the National Academy of Sciences of the United States of America 1991 88 19 8616 8620 2-s2.0-0026005994 10.1073/pnas.88.19.8616 (Pubitemid 21915408)
113. Phillips P. C., Levow C., Catterall M., Colvin O. M., Pastan I., Brem H., Transforming growth factor- α -Pseudomonas exotoxin fusion protein (TGF- α -PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Research 1994 54 4 1008 1015 2-s2.0-0028179159
114. Rand R. W., Kreitman R. J., Patronas N., Varricchio F., Pastan I., Puri R. K., Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clinical Cancer Research 2000 6 6 2157 2165 2-s2.0-0034047780 (Pubitemid 30399180)
115. Lorimer I. A. J., Keppler-Hafkemeyer A., Beers R. A., Pegram C. N., Bigner D. D., Pastan I., Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proceedings of the National Academy of Sciences of the United States of America 1996 93 25 14815 14820 2-s2.0-0029857998 10.1073/pnas.93.25.14815 (Pubitemid 26419052)
116. Pastan I., Hassan R., FitzGerald D. J., Kreitman R. J., Immunotoxin therapy of cancer. Nature Reviews Cancer 2006 6 7 559 565 2-s2.0-33745571528 10.1038/nrc1891 (Pubitemid 43980544)
117. Kreitman R. J., Pastan I., Immunotoxins in the treatment of hematologic malignancies. Current Drug Targets 2006 7 10 1301 1311 2-s2.0-33749432146 10.2174/138945006778559139 (Pubitemid 44509694)
118. Vallera D. A., Myers D. E., Immunotoxins containing ricin. Cancer Treatment and Research 1988 37 141 159 2-s2.0-0024145281
119. Martell L. A., Agrawal A., Ross D. A., Muraszko K. M., Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Research 1993 53 6 1348 1353 2-s2.0-0027474795 (Pubitemid 23097115)
120. Laske D. W., Muraszko K. M., Oldfield E. H., Devroom H. L., Sung C., Dedrick R. L., Simon T. R., Colandrea J., Copeland C., Katz D., Greenfield L., Groves E. S., Houston L. L., Youle R. J., Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 1997 41 5 1039 1051 2-s2.0-0030712969 10.1097/00006123-199711000-00005 (Pubitemid 27475464)
121. Dälken B., Giesübel U., Knauer S. K., Wels W. S., Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. Cell Death and Differentiation 2006 13 4 576 585 2-s2.0-33644955934 10.1038/sj.cdd.4401773
122. Abi-Habib R. J., Liu S., Bugge T. H., Leppla S. H., Frankel A. E., A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. Blood 2004 104 7 2143 2148 2-s2.0-4644221124 10.1182/blood-2004-01-0339 (Pubitemid 39297869)
123. Orozco-Morales M., Sánchez-García F.-J., Guevara-Salazar P., Arrieta O., Hernández-Pedro N. Y., Sánchez-García A., Perez-Madrigal R., Rangel-López E., Pineda B., Sotelo J., Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin. Journal of Cancer Research and Clinical Oncology 2012 138 1 23 33 2-s2.0-84857064068 10.1007/s00432-011-1069-y